AI-CVD vs inHEART Models
AI Verdict
Choose AI-CVD if…
Choose AI-CVD if your primary objective is opportunistic screening for cardiovascular and multisystem diseases using existing CT scans. This platform is ideal for identifying hidden health risks and at-risk individuals early through automated analysis of routine chest and abdominal CTs, without requiring additional imaging, radiation, or workflow disruption.
View AI-CVD →Choose inHEART Models if…
Choose inHEART Models if you require advanced, AI-driven pre-procedural planning and optimization for complex image-guided cardiac ablation procedures. This tool excels at creating highly detailed 3D digital twin models of the heart from CT/MR images, enabling electrophysiologists to enhance treatment strategies and potentially improve procedural efficiency and patient outcomes for conditions like ventricular tachycardia.
View inHEART Models →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AI-CVD | inHEART Models |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Unknown | Cloud-based |
| FDA Status | Unknown | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AI-CVDAI-CVD offers high usability by performing opportunistic screening using existing CT scans, requiring no additional imaging, radiation, contrast, or workflow disruption. This seamless integration into current clinical workflows minimizes burden on staff and patients. While inHEART Models has improved automation for 3D model creation, some reported limitations exist regarding full compatibility with all EAM systems and offline access, suggesting a potentially more involved integration for certain users.
Clinical Value
inHEART ModelsBoth tools offer significant clinical value. AI-CVD provides broad opportunistic screening for early detection of multiple cardiovascular and systemic diseases, impacting a large patient population for preventive care. However, inHEART Models demonstrates a more direct and quantifiable impact on outcomes for a high-acuity, complex procedure (VT ablation), with reported reductions in procedure time by 60% and recurrence rates by 38%, which is a very strong indicator of clinical efficacy.
Pricing & Value
inHEART ModelsWhile both tools maintain opaque pricing, inHEART Models presents a clearer and more quantifiable value proposition. Its documented potential to reduce VT procedure times by 60% and recurrence rates by 38% directly translates into significant cost savings for healthcare providers and improved patient outcomes. This offers a more tangible return on investment compared to the long-term, less immediately quantifiable benefits of early disease detection offered by AI-CVD.
Enterprise Readiness
inHEART ModelsBoth tools are FDA-cleared and cloud-based, indicating a baseline level of readiness. However, inHEART Models explicitly mentions SOC2 compliance and CE MDR certification, which are strong indicators of robust data security, privacy, and adherence to stringent regulatory frameworks. This provides a more definitive assurance of enterprise readiness for large healthcare systems compared to AI-CVD's 'likely' claims for BAA and HIPAA compliance.
Innovation
inHEART ModelsWhile AI-CVD's opportunistic screening for multiple systemic diseases from existing CT scans is innovative for population health, inHEART Models demonstrates a more advanced and transformative application of AI. Its creation of a highly detailed, patient-specific 'digital twin of the heart' for optimizing complex cardiac ablation procedures represents a cutting-edge innovation in interventional cardiology. This technology provides unprecedented precision for procedural planning and guidance in a high-stakes clinical setting.
Support & Docs
TieNeither the provided structured facts nor the web searches yielded specific public information regarding the availability or quality of customer support and documentation for either AI-CVD or inHEART Models. As FDA-cleared medical devices, both are expected to have adequate support, but without specific details, a definitive winner cannot be determined.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AI-CVD | inHEART Models |
|---|---|---|
| Name | AI-CVD | inHEART Models |
| Company | HeartLung Corporation | inHEART |
| Description | FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. | AI-driven software that creates detailed 3D digital twin models of the heart from CT/MR images, optimizing planning and execution of image-guided cardiac ablation procedures. |
| Primary Use Case / Core Functionality | Opportunistic screening for cardiovascular and multisystem diseases using existing CT scans. | Creates detailed 3D digital twin models of the heart from CT/MR images for optimizing planning and execution of image-guided cardiac ablation procedures. |
| Key Measurements / Output | Automated CT-derived anatomical and density-based measurements, Coronary Artery Calcium (CAC) scoring, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry, Epicardial fat volumetry, Aorta and pulmonary artery sizing. | AI-driven digital twin of the heart, Automated segmentation of CT and MR images, Highly detailed, interactive 3D cardiac models, Pre-procedural planning and optimization of treatment strategies, Seamless integration with major electroanatomic mapping (EAM) systems. |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring AI-CVD and inHEART Models.